At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LEGN Legend Biotech
Closed 06-04 16:00:00 EDT
34.20
-1.78
-4.95%
盘后34.79
+0.59+1.73%
19:55 EDT
High35.78Low33.84Vol3.42M
Open35.69D1 Closing35.98Amplitude5.39%
Mkt Cap6.35BTradable Cap2.78BTotal Shares185.74M
T/O118.20MT/O Rate4.20%Tradable Shares81.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

UBS Adjusts Legend Biotech Price Target to $49 From $31, Maintains Buy Rating
MT Newswires Live  ·  06-04 19:52
UBS Adjusts Legend Biotech Price Target to $49 From $31, Maintains Buy Rating
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  06-03 19:31
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Legend Biotech Corporation : H.c. Wainwright Raises Target Price to $65 From $50
THOMSON REUTERS  ·  06-03 18:09
Legend Biotech Corporation : H.c. Wainwright Raises Target Price to $65 From $50
Barclays Remains a Buy on Legend Biotech (LEGN)
TIPRANKS  ·  06-03 16:17
Barclays Remains a Buy on Legend Biotech (LEGN)
U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty
Reuters  ·  06-03 15:55
U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty
BUZZ-Genscript hits 4-week high on associate's promising blood cancer cell therapy
Reuters  ·  06-03 10:16
BUZZ-Genscript hits 4-week high on associate's promising blood cancer cell therapy
Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech
Stock News  ·  06-03 09:26
Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech
Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment
Dow Jones  ·  06-03 01:58
Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment
This Is Why Legend Biotech Stock (LEGN) Was Up Today
TIPRANKS  ·  06-03 01:21
This Is Why Legend Biotech Stock (LEGN) Was Up Today
Legend Biotech rises 29.5%
TIPRANKS  ·  06-03 00:18
Legend Biotech rises 29.5%
Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress
TIPRANKS  ·  06-02 22:06
Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress
Legend Biotech reports 100% response rate in Phase 1 LB2501 in vivo CAR-T trial for relapsed/refractory NHL patients at higher dose cohort
Reuters  ·  06-02 21:32
Legend Biotech reports 100% response rate in Phase 1 LB2501 in vivo CAR-T trial for relapsed/refractory NHL patients at higher dose cohort
BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501
Reuters  ·  06-02 21:30
BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501
Legend Biotech Announces Late-Breaking Oral Presentation at Eha 2026 Showcasing Initial Phase 1 in Vivo CAR-T Data With Lb2501 in Non-Hodgkin Lymphoma (Nhl)
THOMSON REUTERS  ·  06-02 21:30
Legend Biotech Announces Late-Breaking Oral Presentation at Eha 2026 Showcasing Initial Phase 1 in Vivo CAR-T Data With Lb2501 in Non-Hodgkin Lymphoma (Nhl)
Legend Biotech: No Dose-Limiting Toxicities, Serious Adverse Events, or Neurotoxicity Reported
THOMSON REUTERS  ·  06-02 21:30
Legend Biotech: No Dose-Limiting Toxicities, Serious Adverse Events, or Neurotoxicity Reported
Legend Biotech: 100% Orr (6/6) Observed in Dose Level 2 Cohort, Including Cr Rate of 83.3% (5/6) in Patients With Relapsed/ Refractory Nhl
THOMSON REUTERS  ·  06-02 21:30
Legend Biotech: 100% Orr (6/6) Observed in Dose Level 2 Cohort, Including Cr Rate of 83.3% (5/6) in Patients With Relapsed/ Refractory Nhl
Legend's experimental cell therapy shows promise in blood cancer patients
Reuters  ·  06-02 21:30
Legend's experimental cell therapy shows promise in blood cancer patients
Legend Biotech: Data Demonstrates Robust in Vivo CAR-T Expansion Without Lymphodepleting Chemotherapy or Bridging Therapy
THOMSON REUTERS  ·  06-02 21:30
Legend Biotech: Data Demonstrates Robust in Vivo CAR-T Expansion Without Lymphodepleting Chemotherapy or Bridging Therapy
Legend Biotech presents first-in-human LB2102 results in solid tumors
TIPRANKS  ·  06-02
Legend Biotech presents first-in-human LB2102 results in solid tumors
Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs
TIPRANKS  ·  06-01
Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs

Introduction

Company Name.
Legend Biotech
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Legend Biotech Corp is a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's differentiated technology, global development and manufacturing strategy and expertise provide it with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.
Issue price:
--